AlzWIN is looking for carehome partners in Europe.
At carehome settings, AlzWIN can be used as a 1) screening solution during the admission process or 2) monitoring solution after admission to assess memory care needs. It is quick, effortless and proven to be effective at identifying seniors with memore care needs.
- Participants: Carehomes. Participants could include both those who are showing subtle signs of cognitive changes (based on staff observations) and residents with no known cognitive issues. The focus will be on detecting early-stage cognitive decline.
- Training & Feedback: Care staff could receive training on interpreting the results of the AlzWIN screenings and how to respond effectively. Feedback loops could be created, so caregivers can discuss their observations and share any changes they notice in residents’ behavior or cognitive abilities with the team.
b) Screening Process
- Initial Screening: Participants are screened using AlzWIN’s cognitive tests. It takes 1 minute to administer the test and the staff’s involvement is minimal. It is simply done by speaking to a device
- Ongoing Monitoring: After the initial screening, periodic follow-up screenings can be conducted to track changes in cognitive function over time. This can help in spotting early signs of cognitive decline and observing progression.
- Early Detection: The primary goal is to determine whether AlzWIN’s screenings can identify early-stage cognitive deterioration that might be missed in standard assessments or through staff observations alone.
- Personalized Care: Early identification of cognitive issues would allow caregivers to develop more individualized care strategies, offering residents better support and interventions tailored to their needs.
- Improved Caregiver Decision-Making: By having reliable screening data, caregivers and management can make more informed decisions about allocating resources, planning activities, and prioritizing care for residents at risk of further cognitive decline.
Discover more about Seven Point One:
Seven Point One developed AlzWIN, an AI-powered dementia screening tool using verbal fluency. It is done simply by speaking to a device for a minute and it assesses the 1-min voice data using around various data points. It is validated by multiple awards, peer-reviewed publications, and patents. Registered on FDA as a class 2 item and certified with ISO13485:2016 & GMP, it has successfully identified over 9,000 high-risk dementia patients in real-world settings. As the first solution officially adopted by government-operated clinics, AlzWIN is endorsed by leading insurers, pharmaceutical companies, and medical research foundations.
